Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 2/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5362881 | 0.97 | TLR7 (0.45) | STING1TLR7MAPTMEN1GAA | |
| SCHEMBL5362245 | 0.95 | TLR7 (0.43) | STING1TLR7TLR8MEN1GAA | |
| SCHEMBL1043964 | 0.91 | TLR7 (0.41) | TLR7TLR8MEN1GAAKMT2A | |
| SCHEMBL3968312 | 0.91 | TLR7 (0.49) | STING1TLR7PIM1PIM3TLR8 | |
| SCHEMBL24723244 | 0.90 | TLR7 (0.54) | TLR7PIM1PIM3TLR8GAA | |
| SCHEMBL6502549 | 0.89 | MAPT (0.55) | TLR7MAPTMEN1GAAKMT2A | |
| SCHEMBL2510171 | 0.89 | PIM1 (0.46) | STING1TLR7PIM1PIM3TLR8 | |
| SCHEMBL3970752 | 0.89 | TLR7 (0.52) | TLR7GAATP53 | |
| SCHEMBL1949364 | 0.88 | TLR7 (0.47) | TLR7MAPTMEN1GAAKMT2A | |
| SCHEMBL4309229 | 0.88 | STING1 (0.46) | STING1MAPTDRD2MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144822-A1 | PROCESS FOR THE PREPARATION OF A SUBSTITUTED IMIDAZOQUINOLINE | BioNTech SE (DE) | 2022-05-12 | — | — | US | disclosed |
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8178677-B2 | Hydroxyalkyl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| EP-1851224-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006098852-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-6916925-B1 | Dye labeled imidazoquinoline compounds | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1228147-B1 | DYE LABELED IMIDAZOQUINOLINE COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6630588-B2 | Imidazonaphthyridine, imidazopyridine and imidazoquinoline compounds that have immune response modulating activity and that contain a dye moiety, in particular, a fluorescent dye moiety, e.g., dipyrrometheneboron difluoride dyes | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-07 | — | — | US | disclosed |
| US-20020120141-A1 | Dye labeled imidazoquinoline compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-29 | — | — | US | disclosed |
| EP-1228147-A1 | DYE LABELED IMIDAZOQUINOLINE COMPOUNDS | 3M Innovative Properties Company (US) | 2002-08-07 | — | — | EP | disclosed |
| US-6376669-B1 | COMPLEXES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-04-23 | — | — | US | disclosed |
| WO-2001034709-A1 | DYE LABELED IMIDAZOQUINOLINE COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120141-A1 | Dye labeled imidazoquinoline compounds | LY96, CD74, IFNAR1 | STING1 85/4885TLR7 41/4885PIM1 1197/4885 |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | STING1 5/4885TLR7 194/4885PIM1 1569/4885 |
| US-20220144822-A1 | PROCESS FOR THE PREPARATION OF A SUBSTITUTED IMIDAZOQUINOLINE | TLR7, TLR3, TLR4 | STING1 19/4885TLR7 1/4885PIM1 3387/4885 |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | IFNG, IRF3, IFNAR1 | STING1 5/4885TLR7 55/4885PIM1 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.